HIV-1 RNA and viral load

Clinics in Laboratory Medicine

Volumn 22, Issue 3, 2002, Pages 593-610

  Relucio, Karen ^a   Holodniy, Mark ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS RNA;

ANTIVIRAL ACTIVITY; BLOOD DONOR; BLOOD SAMPLING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MONITORING; PATHOGENESIS; PRIORITY JOURNAL; RACE DIFFERENCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEX DIFFERENCE; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

DISEASE PROGRESSION; HIV INFECTIONS; HIV-1; HUMANS; VIRAL LOAD;

EID: 0036719843     PISSN: 02722712     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-2712(02)00008-2     Document Type: Review

References (94)

1. Detection of HIV-1 RNA sequences by in vitro DNA amplification
2. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
3. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection
4. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay
5. The one-tube quantitative HIV-1 RNA NASBA: Precision, accuracy and application
6. Multicenter comparison of Roche COBAS AMPLICOR MONITOR version 1.5, Organon Teknika Nuclisens QT with Extractor, and Bayer Quantiplex Version 3.0 for quantification of human immunodeficiency virus type 1 RNA in plasma
7. A new ultrasensitive assay for quantitation of HIV-1 RNA in plasma
8. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya
9. Time of initiation of antiretroviral therapy: Impact on HIV-1 viremia. The Swiss HIV Cohort Study
10. The emerging genetic diversity of HIV
11. Identification of a new human immunodeficiency virus type 1 distinct from group M and group O
12. Comparison of three different commercial methods for measuring plasma viraemia in patients infected with non-B HIV-1 subtypes
13. Impact of HIV type 1 subtype variation on viral RNA quantitation
14. Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and quantiplex HIV-1 RNA version 3.0
15. Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma
16. Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma
17. Long-term stability of human immunodeficiency virus viral load and infectivity in whole blood
18. Multisite comparison of reproducibility and recovery from the standard and ultrasensitive Roche AMPLICOR HIV-1 MONITOR
19. Performance characteristics of the Quantiplex HIV-1 RNA 3.0 assay for detection and quantitation of human immunodeficiency virus type 1 RNA in plasma
20. Variance of plasma human immunodeficiency virus type 1 RNA levels measured by branched DNA within and between days
21. Variability in repeated consecutive measurements of plasma human immunodeficiency virus RNA in persons receiving stable nucleoside reverse transcriptase inhibitor therapy or no treatment
22. Effect of potentially interfering substances on the measurement of HIV-1 viral load by the bDNA assay
23. The role of gender in HIV progression
24. Gender differences in virologic response to treatment in an HIV-positive population: A cohort study
25. Human immunodeficiency virus RNA levels in US adults: A comparison based upon race and ethnicity
26. Early prognostic indicators in primary perinatal human immunodeficiency virus type 1 infection: Importance of viral RNA and the timing of transmission on long-term outcome
27. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors
28. Evaluation of surrogate markers and clinical outcomes in two-year follow-up of eighty-six human immunodeficiency virus-infected pediatric patients
29. + lymphocyte count in HIV-infected infants and children
30. Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: Experience with fifty-four perinatally infected children
31. Viral load and heterosexual transmission of human immunodeficiency virus type 1
32. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa
33. Management of HIV infection during pregnancy
34. Correlates of mother-to-child human immunodeficiency virus type 1 (HIV-1) transmission: Association with maternal plasma HIV-1 viral load, genital HIV-1 DNA shedding, and breast infections
35. Patterns of viral dynamics during primary human immunodeficiency virus type 1 infection
36. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
37. Longitudinal serum HIV RNA quantification: Correlation to viral phenotype at seroconversion and clinical outcome
38. Virologic and immunologic characterizations of symptomatic and asymptomatic primary HIV-1 infection
39. Longitudinal HIV-1 RNA levels in a cohort of homosexual men
40. Lack of evidence of a stable viral load set point in early stage asymptomatic patients with chronic HIV-1 infection
41. Diagnosis of primary HIV-1 infection
42. Misdiagnosis of HIV infection by HIV-1 plasma viral load testing: A case series
43. Early detection of perinatal human immunodeficiency virus (HIV) type 1 infection using HIV RNA amplification and detection
44. Quantitation of human immunodeficiency virus type 1 RNA in different biological compartments
45. Effect of antiviral treatment on the shedding of HIV-1 in semen
46. Effect of antiretroviral therapy on HIV shedding in semen
47. Cervicovaginal human immunodeficiency virus secretion and plasma viral load in human immunodeficiency virus-seropositive women
48. Correlation of human immunodeficiency virus type 1 RNA levels in blood and the female genital tract
49. Effect of menstrual cycle on HIV-1 levels in the peripheral blood and genital tract
50. Short-course antenatal zidovudine reduces both cervicovaginal human immunodeficiency virus type 1 RNA levels and risk of perinatal transmission
51. Effect of co infection with STDs and of STD treatment on HIV shedding in genital-tract secretions: Systematic review and data synthesis
52. Cell-free virus in breast milk of HIV-1-seropositive women
53. Human immunodeficiency virus load in breast milk, mastitis, and mother-to-child transmission of human immunodeficiency virus type 1
54. Antiretroviral treatment of central nervous system HIV-1 infection: A review
55. Lack of detection of human immunodeficiency virus type 1 in the saliva of infected children and adolescents
56. Hyper-excretion of human immunodeficiency virus type 1 RNA in saliva
57. Progression of HIV in haemophilia
58. Changes in HIV-1 RNA viral load following tuberculin skin test
59. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection: A preliminary study
60. Increase in plasma viral load after oral cholera immunization of HIV-infected subjects
61. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: Impact on plasma levels of HIV type 1 RNA and determinants of antibody response
62. Controlled trial of interleukin-2 infusions in patients infected with human immunodeficiency virus
63. Changes in plasma HIV RNA levels and CD4 cell counts after vaccination of pediatric patients
64. Association of human papillomavirus infection and disease and magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection
65. Association of plasma levels of human immunodeficiency virus type 1 RNA and oropharyngeal Candida colonization
66. Detection of Kaposi's sarcoma-associated herpes virus in peripheral blood cells in human immunodeficiency virus infection: Association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels
67. Interactions between beta-herpes viruses and human immunodeficiency virus in vivo: Evidence for increased human immunodeficiency viral load in the presence of human herpes virus 6
68. The effect of acute infectious illnesses on plasma human immunodeficiency virus (HIV) type 1 load and the expression of serologic markers of immune activation among HIV-infected adults
69. Effect of superimposed infections on viral replication in human immunodeficiency virus type 1-infected children
70. The effect of Plasmodiumfalciparum malaria on HIV-1 RNA blood plasma concentration
71. Hepatitis C virus infection in HIV-infected patients
72. Antiretroviral triple therapy decreases HIV viral load but doeg not alter hepatitis C virus (HCV) serum levels in HIV-HCV-co-infected haemophilia
73. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA
74. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage
75. Plasma levels of monocyte chemoattractant protein-1 but not those of macrophage inhibitory protein-1 alpha and RANTES correlate with virus load in human immunodeficiency virus infection
76. Relationship of plasma HIV-RNA levels and levels of TNF-alpha and immune activation products in HIV infection
77. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir
78. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy
79. Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy
80. Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment
81. HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment
82. Short-cycle structured intermittent treatment of chronic HIV infection with highly active antiretroviral therapy: Effects on virologic, immunologic, and toxicity parameters
83. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
84. Sexual transmission f an HIV-1 variant resistant to multiple reverse transcriptase and protease inhibitors
85. Prevalence and predictive value of intermittent viremia with combination HIV therapy
86. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
87. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease
88. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
89. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA
90. Results of national testing of US blood donations for HIV-1 p 24 antigen
91. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases
92. False-positive HIV-1 test results in a low-risk screening setting of voluntary blood donation
93. Viral load and disease progression in infants infected with human immunodeficiency virus type 1